Protokylol

Summary

Protokylol (CHEMBL1201273) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 331.4 Da · C18H21NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201273
Name	Protokylol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4969
Molecular formula	C18H21NO5
Molecular weight	331.4
InChIKey	LUMAEVHDZXIGEP-UHFFFAOYSA-N

SMILES: CC(CC1=CC2=C(C=C1)OCO2)NCC(C3=CC(=C(C=C3)O)O)O

IUPAC name: 4-[2-[1-(1,3-benzodioxol-5-yl)propan-2-ylamino]-1-hydroxyethyl]benzene-1,2-diol

Also known as: Asmeti, Caytine, Protokylol, Protoquilol, Palisan, PROTOKYLOL

Parent form; salt/anhydrous children: CHEMBL1200893

Patent coverage: 562 distinct patent families (1,895 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).